ClinicalTrials.gg
Not yet recruitingNCT07409480ImmugoldUpdated Feb 18, 2026

Design and Development of a Functional Plant-based Beverage to Improve Nutritional Status and Immunity for the Early Elderly People to Get Well-healthy Ageing

An interventional study of Functional plant-based beverage and Control Beverage in Inflammation and Immune System, sponsored by University Rovira i Virgili. Not yet recruiting at 1 site in Spain. Open to participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.

Primary conditionInflammation(the registry's first term)UnverifiedIs this wrong?Inflammation is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by University Rovira i Virgili · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Study summary

In 2018, for the first time, the number of people aged 65 and over exceeded the number of children under the age of 5. A rise in ageing societies is coming, and new efforts are needed to ensure that this increase in life expectancy is accompanied by years of health and a good quality of life. The new focus for our ageing society will be an extended healthspan, the period of life spent in good health. This is an important shift, as population ageing is a defining global trend of our time. By 2030, 1 in 6 people in the world will be 60 years and older, according to the World Health Organization. In this sense, the imperative to maintain the health and activity levels of the senior demographic has never been more critical. Advances in healthcare, science, and technology have contributed to increased longevity, yet this does not always equate to improved health.

The prevalence of malnutrition or the risk thereof among the elderly living independently in Europe ranges from 13.5% to 29.7%, highlighting a pressing need for nutritional intervention. Addressing this, the pursuit of innovative nutritional sources and the creation of new food products enriched with these sources are essential to bridging the nutritional gap, ensuring healthier aging prospects for this population. The formulation of food products tailored to the elderly must consider their unique nutritional requirements, particularly concerning protein and micronutrient intake. Recent advances in food technology facilitate the development of plant-based beverages that are palatable, nutritionally adequate, and accessible. Moreover, the growing market share of plant-based non-dairy beverages provides a promising alternative, offering opportunities to deliver bioactive compounds with health-promoting properties, appealing to health-conscious and lactose-intolerant consumers.

Given the nutritional challenges and health risks faced by the aging population, particularly in relation to protein intake and malnutrition, another critical aspect that warrants attention is the immune system's health through diet. The immune system, which naturally weakens with age, plays a crucial role in the elderly's ability to resist infections and recover from illnesses. Research highlights the impact of not only macronutrients but micronutrients such as vitamins D, C, E, and zinc on enhancing immune responses, suggesting that diets rich in these nutrients can significantly benefit immune health in older adults. Strengthening the immune system through diet becomes even more pertinent considering the increased vulnerability of the elderly to infectious diseases, including respiratory infections like influenza and pneumonia, which are leading causes of morbidity and mortality in this population. Developing food products that are not only nutritionally adequate but also tailored to support immune function could provide a dual benefit: improving general health and enhancing the body's defence mechanisms.

The present research project is structured into three coordinated phases and is enabled by the multidisciplinary nature of the IMMUGOLD consortium. In the first phase, AZTI conducted an extensive literature and technical review to identify functional ingredients capable of supporting immune function while remaining compatible with the technological, sensory, and stability requirements of a plant-based beverage. This process identified vitamin D, zinc, FOS, and L-leucine as the most suitable bioactive components, considering bioavailability, processing stability, and expected physiological effects. In the second phase, COSTA carried out the development and reformulation of the oat-based beverage to ensure nutritional adequacy, ingredient stability under thermal treatment, and organoleptic acceptability for older consumers. Finally, the third phase involves a clinical study, to be executed by Universitat Rovira i Virgili (URV), which aims to evaluate the effects of the newly developed fortified beverage on markers of immune function and systemic inflammation in community-dwelling older adults, with secondary outcomes including nutritional status and other health-related parameters relevant to ageing.

The multidisciplinary expertise of the consortium, including computational modelling, ingredient research, nutrition, food product development, and clinical epidemiology, ensures the feasibility of the project and the successful achievement of its objectives: AZTI provides evidence-based solutions for functional ingredients; COSTA develops innovative plant-based beverages; and URV contributes extensive experience in designing and implementing nutritional programs and clinical studies.

Read the detailed description

Randomised, placebo-controlled, parallel, and double-blind intervention study.

There will be 4 visits in total, attended in the Centre MQ Reus:

  • Screening visit (V0, week -1):

    • Information to the volunteer and signature of the informed consent.
    • Revision of the eligibility criteria.
    • Elaboration of study clinical history.
    • Vital signs (blood pressure/resting heart rate).
    • Checking the concomitant medication.
    • Capillary blood sampling (Finger-prick blood sampling).
    • Anthropometry: waist circumference; hip; body weight and composition; height.
    • Delivery of the 3-day dietary record and the material for urine, saliva, and faeces recollection for V1.
    • Schedule the first visit and instructions (fasting).

      - Basal visit (V1, week 0):

    • Isokinetic assessment (±5 days V1) *
    • Revision of the study clinical history.
    • Vital signs (blood pressure/resting heart rate).
    • Checking the concomitant medication.
    • Anthropometry: waist circumference; hip; body weight and composition; height.
    • Checking the physical activity (IPAQ-E).
    • Checking the quality of life (SF-36 Health survey questionnaire)
    • Checking the Fraility
    • Checking the Sleep quality
    • Checking the Depressive symptoms
    • Checking the Cognitive function (MMSE and Fototest)
    • Checking the Reported illness (adapted version of the FLU-PRO plus)
    • Ultrasound (muscle mass and abdominal fat).
    • Checking the Sarcopenic parameters (muscle strength based on grip dynamometry; skeletal muscle mass index (SMI) based on bioimpedance analysis (BIA), kg/m2 and appendicular skeletal muscle mass index (ASMI) based on bioimpedance analysis (BIA), low physical performance or physical function based on 4 m gait speed, m/s.
    • Checking the 3-day dietary record
    • Checking the Food Frequency Questionnaire (FFQ) adapted to the principal bioactive compounds (vitamin D, L-leucin, Zinc and FOS).
    • Checking the satiety scale (VAS)
    • Checking the Gastrointestinal health by Bristol Scale and Non-validated 5-item questionnaire
    • Blood sample extraction.
    • Collection of feaces samples.
    • Collection of urine samples.
    • Collection of salivary samples.
    • Balanced dietary guidelines for the elderly population explanation.
    • Schedule the next visit and instructions.
    • Administration of plant-based beverage (intervention or control product).
    • Assessment of product acceptance and purchase intention (After the first few home intakes (Week 1) by telephone) *In a subsample of n= 15 subjects, 5 days before or after the visit V10.

      **Isokinetics analysis in order to measure changes in muscle function through variables such as torque, work and power.

      • Mid-study follow-up visit V2 (weeks 6):
    • Revision of study clinical history.
    • Vital signs (blood pressure/resting heart rate).
    • Checking the concomitant medication.
    • Checking the physical activity (IPAQ-E).
    • Checking the Reported illness (adapted version of the FLU-PRO plus)
    • Checking the FFQ
    • Product intake control
    • Record adverse effects
    • Delivery of the 3-day dietary record and the material for urine, saliva and faeces recollection for V3.
    • Schedule the next visit and instructions.
    • Administration of plant-based beverage (intervention or control product). - Final visit (V3 at week 12):
    • Isokinetic assessment (±5 days V1)*
    • Revision of study clinical history.
    • Vital signs (blood pressure/resting heart rate).
    • Checking the concomitant medication.
    • Anthropometry: waist circumference; hip; body weight and composition; height.
    • Checking the physical activity (IPAQ-E).
    • Checking the quality of life (SF-36 Health survey questionnaire)
    • Checking the Fraility
    • Checking the Sleep quality
    • Checking the Depressive symptoms
    • Checking the Cognitive function (MMSE and Fototest)
    • Checking the Reported illness (adapted version of the FLU-PRO plus)
    • Ultrasound (muscle mass and abdominal fat).
    • Checking the Sarcopenic parameters (muscle strength based on grip dynamometry; skeletal muscle mass index (SMI) based on bioimpedance analysis (BIA), kg/m2 and appendicular skeletal muscle mass index (ASMI) based on bioimpedance analysis (BIA), low physical performance or physical function based on 4 m gait speed, m/s.
    • Checking the 3-day dietary record
    • Checking the Food Frequency Questionnaire (FFQ) adapted to the principal bioactive compounds (vitamin D, L-leucin, Zinc and FOS).
    • Checking the satiety scale (VAS)
    • Checking the Gastrointestinal health by Bristol Scale and Non-validated 5-item questionnaire
    • Blood sample extraction.
    • Collection of feaces samples.
    • Collection of urine samples.
    • Collection of salivary samples.
    • Product intake control
    • Record adverse effects
    • Assessment of product acceptance and purchase intention *In a subsample of n= 15 subjects, 5 days before or after the visit V10.

      • Isokinetics analysis in order to measure changes in muscle function through variables such as torque, work and power.

In visits V0, V1 and V3 volunteers must present themselves in fasting conditions of 8 hours to obtain fasting blood samples.

- Assessment of product acceptance and purchase intention Acceptance will be assessed at baseline and at the final visit and purchase intention will be assessed at the final visit. The questionnaire is short, requires only a few minutes to complete, and will be administered verbally in person (V3), or by phone (after V1, during the first week).

The questionnaire includes an evaluation of several attributes of the product. Participants are asked to rate each aspect on a scale from 1 to 5, where 1 indicates that the attribute is "very unpleasant" and 5 indicates that it is "very pleasant," with the option to use intermediate values to better reflect their opinion. The attributes assessed are colour, smell, appearance, flavour, texture, sweetness (in this case, 1 meaning "not sweet" and 5 meaning "very sweet"), and overall acceptance of the product.

Additionally, participants are asked to rate their intention to purchase the product on a scale from 1 to 5, where 1 corresponds to "very unlikely" and 5 to "very likely." Finally, an open section is provided for any additional comments or observations the participant may wish to share.

02

Conditions studied

  • Inflammation
  • Immune System

Browse trials for

Keywords

  • inflammation
  • immune system
  • nutritional status
  • sarcopenia
  • cognitive impairment
03

In context

Inflammation Unverified

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

This study's planned enrollment of 70 is above the median of 50 across 2,586 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

University Rovira i Virgili is the lead sponsor of 53 studies on the registry; 10 are open to participants now.

Compared within Inflammation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ≥60 years old \<80 years old.
  • Written provided before the initial screening visit.

Exclusion criteria

Exclusion Criteria:

  • Hypoglycaemic treatment or type 1 and type 2 diabetes mellitus diagnosed.
  • Anaemia ( ≤13 g/dL in men and ≤12 g/dL in women).
  • Intestinal malabsorption diseases, such as chron disease, colitis ulcerous, and irritable bowel syndrome.
  • Immune pathology or depressed immune system.
  • Use of antioxidants or nutritional supplements.
  • Known allergy or to oat, coconut, or any formulation ingredient.
  • Renal diseases or history of hypercalcemia, sarcoidosis, or hyperparathyroidism.
  • History of inborn errors of metabolism affecting branched-chain amino acid metabolism.
  • Chronic alcoholism.
  • Current or past participation in a clinical trial or consumption of a research product in the 30 days before inclusion in the study.
  • Failure to follow the study guidelines.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Functional plant-based beverage

    250 mL/day of the multi-ingredient plant-based functional beverage consumed at any time throughout the day + balanced dietary recommendations for the elderly population.

    Dietary Supplement: Functional plant-based beverage

  • Placebo comparator
    Control beverage

    250mL/day of the plant-based beverage without functional selected study ingredients consumed at any time throughout the day + balanced dietary recommendations for the elderly population.

    Dietary Supplement: Control Beverage

Interventions

  • Dietary supplementFunctional plant-based beverage

    250 mL/day of the multi-ingredient plant-based functional beverage consumed at any time throughout the day + balanced dietary recommendations for the elderly population.

  • Dietary supplementControl Beverage

    250mL/day of the plant-based beverage without functional selected study ingredients consumed at any time throughout the day + balanced dietary recommendations for the elderly population.

06

What researchers measure

Primary outcomes

  1. Change in serum hsCRP

    The primary outcome measure will be the change in serum hsCRP (mg/dL) assessed by high-sensitivity immunoturbidimetry standardized methods on a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain). It has been suggested that values \> 0.2 mg/dL of hsCRP increased the likelihood of developing cardiovascular disease or ischemic events. Consequently, changes in hsCRP involve changes in clinical impact.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

Secondary outcomes

  1. Inflammation markers and inflammatory cytokines

    Interleukin-1 beta (IL-1β) (pg/mL) assessed by commercial multi-analyte ELISArray kits (R\&D Systems) in blood samples.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  2. Inflammation markers and inflammatory cytokines

    Interleukin-6 (IL-6) (pg/mL) assessed by commercial multi-analyte ELISArray kits (R\&D Systems) in blood samples.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  3. Inflammation markers and inflammatory cytokines

    Interleukin-10 (IL-10) (pg/mL) assessed by commercial multi-analyte ELISArray kits (R\&D Systems) in blood samples.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  4. Inflammation markers and inflammatory cytokines

    Uric acid (mg/dL) assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  5. Inflammation markers and inflammatory cytokines

    Homocysteine (µmol/L) assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  6. Inflammation markers and inflammatory cytokines

    Intercellular Adhesion Molecule-1 (ICAM-1) (ng/mL) assessed by commercial multi-analyte ELISArray kits (R\&D Systems) in blood samples.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  7. Inflammation markers and inflammatory cytokines

    Vascular Cell Adhesion Molecule 1 (VCAM-1) (ng/mL) assessed by commercial multi-analyte ELISArray kits (R\&D Systems) in blood samples.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  8. Inflammation markers and inflammatory cytokines

    Tumor necrosis factor receptor 1 (TNFR-1) (ng/mL) assessed by commercial ELISA in blood samples.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  9. Oxidative markers

    Oxidized LDL (oxLDL) (ug/mL) assessed by commercial ELISA in blood samples

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  10. Oxidative markers

    Oxidized methionine (Met/SO/Met) (ng/mL) assessed by commercial ELISA in blood samples

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  11. Oxidative markers

    Superoxide Dismutase (SOD) (U/g Hb) assessed by enzymatic assays in blood samples

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  12. Oxidative markers

    Glutathione peroxidase (GSHPx) (nmol/mL) assessed by enzymatic assays in blood samples

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  13. Immunologic parameters

    Lymphocytes T cells (CD4 and CDB) (cells/µL) assessed by ELIspot in blood samples

    Time frame: Visit 1 ("week 0", visit 3 ("week 12")

  14. Immunologic parameters

    Lymphocytes B cells (cells/µL) assessed by immunofluorescence in blood samples.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  15. Immunologic parameters

    Immunoglobulins (IgM) (cells/µL) assessed by ELISA kits in serum samples.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  16. Immunologic parameters

    Immunoglobulins (IgG) (cells/µL) assessed by ELISA kits in serum samples.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  17. Immunologic parameters

    Immunoglobulins (IgA) (cells/µL) assessed by ELISA kits in saliva samples.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  18. Immunologic parameters

    Immunoglobulins (IgE) (cells/µL) assessed by ELISA kits in serum samples.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  19. Glucose homeostasis

    Fasting blood glucose (FBG) (mmol/L) assessed by standardized methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  20. Glucose homeostasis

    Insulin (IU/mL) assessed by standardized methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples

    Time frame: Visit 1 ("week 0", visit 3 ("week 12")

  21. Glucose homeostasis

    HGBA1c (%) assessed by standardized methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland) in blood samples

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  22. Glucose homeostasis

    Homeostasis model assessment index (HOMA-i) calculated from fasting glucose and insulin.

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  23. Lipid profile

    Total analyser (TC) (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland).

    Time frame: visit 1 ("week 0"), visit 3 ("week 12")

  24. Lipid profile

    High-density lipoprotein analyser (HDL-c) (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland).

    Time frame: visit 1 ("week 0"), visit 3 ("week 12")

  25. Lipid profile

    Low-density lipoprotein analyser (LDL-c) (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland).

    Time frame: visit 1 ("week 0"), visit 3 ("week 12")

  26. Lipid profile

    Triglycerides (TG) (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland).

    Time frame: visit 1 ("week 0"), visit 3 ("week 12")

  27. Lipid profile

    Non-esterified fatty acids (NEFA) (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland).

    Time frame: visit 1 ("week 0"), visit 3 ("week 12")

  28. Lipid profile

    Apolipoprotein A1 (ApoA1) (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland).

    Time frame: visit 1 ("week 0"), visit 3 ("week 12")

  29. Lipid profile

    Apolipoprotein B100 (ApoB100) (mmol/L) in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland).

    Time frame: visit 1 ("week 0"), visit 3 ("week 12")

  30. Lipid profile

    Apo B100/ Apo A1 ratio in blood samples assessed by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland).

    Time frame: Visit 1 ("Week 0"), visit 3 ("Week 12")

  31. Anthropometric and muscle health measurements

    Waist circumference (cm) measured by steel measuring tape (at the umbilicus).

    Time frame: Visit 0 ("week -1"), visit 1 ("week 0"), visit 3 ("week 12")

  32. Anthropometric and muscle health measurements

    Hip circumference (cm) measured by steel measuring tape.

    Time frame: Visit 0 ("week -1"), visit 1 ("week 0"), visit 3 ("week 12")

  33. Anthropometric and muscle health measurements

    Heigh (cm) measured by wall-mounted stadiometer (Tanita Leicester Portable; Tanita Corp., Barcelona, Spain)

    Time frame: Visit 0 ("week -1"), visit 1 ("week 0"), visit 3 ("week 12")

  34. Anthropometric and muscle health measurements

    Body mass index (BMI) (kg/m²), calculated as weight (kg) divided by height squared (m²).

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  35. Anthropometric and muscle health measurements

    Body weight and composition assessed by calibrated scale (TANITA MC-780MA; Tanita Corp., Tokyo, Japan).

    Time frame: Visit 0 ("week -1"), visit 1 ("week 0"), visit 3 ("week 12")

  36. Anthropometric and muscle health measurements

    Abdominal fat distribution measured by ultrasound (VINNO 5 (Vinno (Suzhou) Co., Ltd., China)

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  37. Anthropometric and muscle health measurements

    Muscle mass quantity and quality assessed by quadriceps ultrasound (VINNO 5 (Vinno (Suzhou) Co., Ltd., China).

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  38. Anthropometric and muscle health measurements

    Grip strength (kg) handheld dynamometer and the maximum value from either hand will be analysed (Jamar dynamometer; Sammons Preston Rolyan, Bolingbrook, IL)

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  39. Anthropometric and muscle health measurements

    Physical performance (m/s) assessed by the length of the walking course divided by the time

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  40. Anthropometric and muscle health measurements

    Isokinetic test (°s-1): the evaluation was conducted with an isokinetic dynamometer using a gold standard method (Biodex System 4; Biodex Medical Systems, NewYork, USA) by five repetitions sat two angular velocities (180°s-1, and 240°s-1). This allows a quantitative evaluation of muscle function through variables such as torque, work and power (in a subsample).

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  41. Circulating micronutrients levels

    Serum concentrations of 25-hydroxivitamin D \[25(OH)D\] will be quantified as the primary biomarker of vitamin D status using a validated laboratory assay.

    Time frame: Visit 1 ("week 1"), visit 3 ("week 12")

  42. Circulating micronutrients levels

    β-Hydroxy-β-methylbutyrate (HMB): Serum HMB concentrations will be measured as a functional biomarker of L-leucine intake and metabolism using a validated laboratory assay.

    Time frame: Visit 1 ("week 1"), visit 3 ("week 12")

  43. Reported illness

    To monitor global illness-like symptoms (respiratory, gastrointestinal, systemic) throughout the intervention period, we will use a shortened and adapted version of FLU-PRO Plus.

    Time frame: Visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12")

  44. Physical activity

    International physical activity questionnaire for elderly: IPAQ for elderly. IPAQ-E Spanish version. Higher scores mean a better outcome.

    Time frame: Visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12")

  45. Dietary record

    Food Frequency Questionnaire adaptet to the principal bioactive compounds assessed by standardized tests.

    Time frame: Visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12")

  46. Dietary record

    3-day dietary record assessed by a nutritional composition database.

    Time frame: Visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12")

  47. Life Quality

    SF-36 Health survey questionnaire. Higher scores mean a better outcome.

    Time frame: Visit 1 ("week 1"), visit 3 ("week 12")

  48. Frailty assessment

    Fried frailty phenotype (weight loss, exhaustion, grip strenght, low physical activity, slow walking pace)

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  49. Sleep Quality

    Assessed by Pittsburgh Sleep Quality Index. The maximum score is 21 points. More than 5 points are considered bad outcomes and sleep problems, and less than 5 points are considered better outcomes and no sleep problems.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  50. Depressive symptoms

    Assessed by Geriatric Depression Scale Questionnaire. The maximum puntuation is 15. The score is 0-4 no depression, 5-8 mild depression, 9-11 moderate depression and 12-15 severe depression.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  51. Cognitive Function

    Spanish validated Mini Mental State Examination test (MMSE). The MMSE test various cognitive. The total test score ranges from 0 (impaired) to 30 (normal).

    Time frame: Visit 1 ("Week 0"), visit 3 ("week 12")

  52. Cognitive Function

    Fototest. The Fototest is a brief and practical tool useful for identifying cognitive impairment and dementia in routine clinical practice.

    Time frame: Visit 1 ("Week 0"), visit 3 ("week 12")

  53. Gut microbiota

    Phyla composition functionality: Whole genomic content sequencing. Illumina platform will be used to obtain the metagenomics and metatranscriptomics of each sample following previous protocols developed in FISABIO-Salud Pública (Valencia).

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  54. Gut microbiota

    Short chain fatty acids (µmol/g) assessed by gas chromatography in faecal samples.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  55. Gut microbiota

    Bile acids (µmol/g) assessed by gas chromatography in faecal samples.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  56. Gut microbiota

    Sterols (µg/g) assessed by gas chromatography in faecal samples.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  57. Gut microbiota

    Faecal metabolites: buthyrate (µmol/g) assessed by gas chromatography analysis coupled to a flame ionization detector.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  58. Gut microbiota

    Branched chain amino acids (BCAA) (µmol/L) assessed by nuclear magnetic resonance in a Vantera clinical spectometer (LipoScience; Raleigh, NC, USA) in faecal samples.

    Time frame: Visit 1 ("week 0"), visit 3 ("week 12")

  59. Vital Signs

    Blood pressure (mmHg) assessed by OMRON M6 Comfort (HEM-7360-E)

    Time frame: Visit 0 ("Week -1"), visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12")

  60. Vital Signs

    Resting heart rate (bpm) assessed by OMRON M6 Comfort (HEM-7360-E)

    Time frame: Visit 0 ("Week -1"), visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12")

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for May 2027, 15 months later.

Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 15 months is below that.

Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 13, 2026
StartEst.
Feb 9, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409480
Lead sponsor
University Rovira i Virgili
Responsible party
Anna Pedret (Professor, Dr., University Rovira i Virgili) — Principal investigator
First posted
Feb 13, 2026
Start date
Feb 9, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Anna Pedret Figuerola, Doctor
Contact
anna.pedret@urv.cat
+34 977 759 375

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion